Piiparinen Heli, Höckerstedt Krister, Lappalainen Maija, Suni Jukka, Lautenschlager Irmeli
Department of Virology, Transplantation and Liver Surgery Unit, Helsinki University, Finland.
J Clin Microbiol. 2002 Aug;40(8):2945-52. doi: 10.1128/JCM.40.8.2945-2952.2002.
A quantitative PCR test, the Cobas Amplicor CMV Monitor, was used for the monitoring of viral load in the peripheral blood of 27 individual liver transplant patients and correlated with cytomegalovirus (CMV) pp65 antigenemia. Altogether, 243 specimens were analyzed. During the first 3 months, 20 patients showed PCR positivity which correlated with pp65 antigenemia. Of those, 13 patients developed symptomatic CMV infection 27 to 52 days after transplantation, with a significantly higher peak viral load in PCR and in pp65 assay compared with the seven asymptomatic infections (median 10,200 versus 2,240 copies/ml, P < 0.05, and median 100 versus 30 pp65-positive cells/50,000 leukocytes, P < 0.01). Five were primary infections of D+/R- cases (donor CMV seropositive and recipient seronegative) and demonstrated, except in one case, a high peak viral load (>10,000 copies/ml; range, 10,200 to 21,600 copies, and > or =50 positive cells, range, 50 to 800 cells). The peak viral loads of the six D+/R+ patients with symptomatic infection varied widely (range, 2,290 to 126,000 copies and 50 to 300 positive cells). Two D-/R+ patients developed symptomatic infection with a lower viral load (range, 1,120 to 6,510 copies and 25 to 100 positive cells). All symptomatic infections were successfully treated with ganciclovir. The asymptomatic infections all in D+/R+ patients with low copy numbers (<5,500 copies) were monitored until CMV disappeared. One of the seven PCR-negative patients had one sample with low antigenemia, but the subsequent specimens were all negative. The time-related correlation of the two methods was also good. In summary, quantitative PCR could equally well be used as the CMV pp65 assay for the monitoring of viral load in individual transplant patients.
采用定量聚合酶链反应(PCR)检测法(Cobas Amplicor CMV Monitor)对27例肝移植患者外周血中的病毒载量进行监测,并与巨细胞病毒(CMV)pp65抗原血症进行相关性分析。共分析了243份标本。在最初的3个月内,20例患者PCR检测呈阳性,且与pp65抗原血症相关。其中,13例患者在移植后27至52天发生有症状的CMV感染,与7例无症状感染相比,其PCR和pp65检测中的病毒载量峰值显著更高(中位数分别为10200拷贝/毫升和2240拷贝/毫升,P<0.05;中位数分别为100个和30个pp65阳性细胞/50000个白细胞,P<0.01)。5例为D+/R-病例(供体CMV血清学阳性而受体血清学阴性)的原发性感染,除1例病例外,均表现出较高的病毒载量峰值(>10000拷贝/毫升;范围为10200至21600拷贝,且≥50个阳性细胞,范围为50至800个细胞)。6例有症状感染的D+/R+患者的病毒载量峰值差异很大(范围为2290至126000拷贝,50至300个阳性细胞)。2例D-/R+患者发生有症状感染,病毒载量较低(范围为1120至6510拷贝,25至100个阳性细胞)。所有有症状感染均用更昔洛韦成功治疗。对D+/R+患者中所有低拷贝数(<5500拷贝)的无症状感染进行监测,直至CMV消失。7例PCR阴性患者中有1例有一份样本抗原血症较低,但随后的标本均为阴性。两种方法的时间相关性也很好。总之,定量PCR可同样有效地用作CMV pp65检测法,用于监测个体移植患者的病毒载量。